HRP20221383T1 - Kombinacije elemenata ekspresijskog vektora, novi proizvodni postupci dobivanja stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida - Google Patents
Kombinacije elemenata ekspresijskog vektora, novi proizvodni postupci dobivanja stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida Download PDFInfo
- Publication number
- HRP20221383T1 HRP20221383T1 HRP20221383TT HRP20221383T HRP20221383T1 HR P20221383 T1 HRP20221383 T1 HR P20221383T1 HR P20221383T T HRP20221383T T HR P20221383TT HR P20221383 T HRP20221383 T HR P20221383T HR P20221383 T1 HRP20221383 T1 HR P20221383T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- nucleic acid
- acid encoding
- expression
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 17
- 239000013604 expression vector Substances 0.000 title claims 10
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 18
- 108020004707 nucleic acids Proteins 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 13
- 210000004962 mammalian cell Anatomy 0.000 claims 10
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 6
- 239000003550 marker Substances 0.000 claims 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 4
- 239000002299 complementary DNA Substances 0.000 claims 3
- 239000013613 expression plasmid Substances 0.000 claims 3
- 230000016784 immunoglobulin production Effects 0.000 claims 2
- 101001002317 Homo sapiens Gastrin Proteins 0.000 claims 1
- 108010006025 bovine growth hormone Proteins 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Claims (24)
1. Postupak za odabir rekombinantne stabilne transficirane stanice sisavca naznačen time, da obuhvaća sljedeće korake:
a) transficiranje stanice sisavca s ekspresijskim vektorom koji sadrži
- prvu ekspresijsku kasetu koja u smjeru od 5' do 3' sadrži promotor hCMV virusa, nukleinsku kiselinu koja kodira laki lanac protutijela, signalni slijed bGH polyA i terminacijski slijed hGT,
- drugu ekspresijsku kasetu koja u smjeru od 5' do 3' sadrži promotor hCMV virusa, nukleinsku kiselinu koja kodira teški lanac protutijela, signalni slijed bGH polyA i terminacijski slijed hGT,
pri čemu su prva ekspresijska kaseta i druga ekspresijska kaseta raspoređene jednosmjerno,
čime se dobiva mnoštvo rekombinantnih stanica sisavca,
b) odabiranje iz mnoštva rekombinantnih stanica sisavca (jedne) stabilno transficirane rekombinantne stanice sisavca, pri čemu u staničnim linijama, koje se dobivaju transficiranjem i odabirom stabilnih staničnih klonova, kombinacija signalnog slijeda goveđeg hormona rasta polyA i terminacije humanog gastrina rezultira u poboljšanom prinosu ekspresije protutijela.
2. Postupak prema patentnom zahtjevu 1, naznačen time, da nukleinska kiselina koja kodira laki lanac protutijela i/ili nukleinska kiselina koja kodira teški lanac protutijela sadrži barem jedan intron.
3. Postupak prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time, da nukleinska kiselina koja kodira laki lanac protutijela i/ili nukleinska kiselina koja kodira teški lanac protutijela jest cDNA.
4. Postupak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da ekspresijski plazmid nadalje sadrži selekcijski marker.
5. Postupak prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da su ekspresijske kasete i selekcijski marker raspoređeni jednosmjerno.
6. Postupak prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da su ekspresijske kasete raspoređene u nizu LC-HC-SM.
7. Postupak prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da je stanica sisavca odabrana iz CHO stanica, HEK stanica, BHK stanica, NS0 stanica i SP2/0 stanica.
8. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da stanica sisavca je CHO stanica za odabir stabilno transficirane stanice.
9. Postupak za proizvodnju protutijela, naznačen time, da obuhvaća sljedeće korake:
a) kultivacija stanice sisavca koja sadrži
- prvu ekspresijsku kasetu koja u smjeru od 5' do 3' sadrži promotor hCMV virusa, nukleinsku kiselinu koja kodira laki lanac protutijela, signalni slijed bGH polyA i terminacijski slijed hGT,
- drugu ekspresijsku kasetu koja u smjeru od 5' do 3' sadrži promotor hCMV virusa, nukleinsku kiselinu koja kodira teški lanac protutijela, signalni slijed bGH polyA i terminacijski slijed hGT, i
b) vraćanje protutijela iz stanice ili kultivacijskog medija,
pri čemu su prva ekspresijska kaseta i druga ekspresijska kaseta raspoređene jednosmjerno za stabilnu proizvodnju protutijela.
10. Postupak prema patentnom zahtjevu 9, naznačen time, da nukleinska kiselina koja kodira laki lanac protutijela i/ili nukleinska kiselina koja kodira teški lanac protutijela sadrži barem jedan intron.
11. Postupak prema bilo kojem od patentnih zahtjeva 9 do 10, naznačen time, da nukleinska kiselina koja kodira laki lanac protutijela i/ili nukleinska kiselina koja kodira teški lanac protutijela jest cDNA.
12. Postupak prema bilo kojem od patentnih zahtjeva 9 do 11, naznačen time, da ekspresijski plazmid nadalje sadrži selekcijski marker.
13. Postupak prema bilo kojem od patentnih zahtjeva 9 do 12, naznačen time, da su ekspresijske kasete i selekcijski marker raspoređeni jednosmjerno.
14. Postupak prema bilo kojem od patentnih zahtjeva 9 do 13, naznačen time, da su ekspresijske kasete raspoređene u nizu LC-HC-SM.
15. Postupak prema bilo kojem od patentnih zahtjeva 9 do 14, naznačen time, da je stanica sisavca odabrana iz CHO stanica, HEK stanica, BHK stanica, NS0 stanica i SP2/0 stanica.
16. Postupak prema bilo kojem od patentnih zahtjeva 9 do 15, naznačen time, da stanica sisavca je CHO stanica za stabilnu proizvodnju protutijela.
17. Ekspresijski vektor, naznačen time, da sadrži
- prvu ekspresijsku kasetu koja u smjeru od 5' do 3' sadrži promotor hCMV virusa, nukleinsku kiselinu koja kodira laki lanac protutijela, signalni slijed bGH polyA i terminacijski slijed hGT,
- drugu ekspresijsku kasetu koja u smjeru od 5' do 3' sadrži promotor hCMV virusa, nukleinsku kiselinu koja kodira teški lanac protutijela, signalni slijed bGH polyA i terminacijski slijed hGT.
18. Ekspresijski vektor prema patentnom zahtjevu 17, naznačen time, da nukleinska kiselina koja kodira laki lanac protutijela i/ili nukleinska kiselina koja kodira teški lanac protutijela sadrži barem jedan intron.
19. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 17 do 18, naznačen time, da nukleinska kiselina koja kodira laki lanac protutijela i/ili nukleinska kiselina koja kodira teški lanac protutijela jest cDNA.
20. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 17 do 19, naznačen time, da su prva ekspresijska kaseta i druga ekspresijska kaseta raspoređene jednosmjerno za odabir stabilno transficirane stanice.
21. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 17 do 20, naznačen time, da ekspresijski plazmid nadalje sadrži selekcijski marker.
22. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 17 do 21, naznačen time, da su ekspresijske kasete i selekcijski marker raspoređeni jednosmjerno.
23. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 17 do 22, naznačen time, da su ekspresijske kasete raspoređene u nizu LC-HC-SM.
24. Eukariotska stanica, naznačena time, da sadrži ekspresijski vektor prema bilo kojem od patentnih zahtjeva 17 do 22.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11195361 | 2011-12-22 | ||
| PCT/EP2012/076203 WO2013092743A2 (en) | 2011-12-22 | 2012-12-19 | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
| EP12810245.6A EP2794651B1 (en) | 2011-12-22 | 2012-12-19 | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221383T1 true HRP20221383T1 (hr) | 2023-01-06 |
Family
ID=47504950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221383TT HRP20221383T1 (hr) | 2011-12-22 | 2012-12-19 | Kombinacije elemenata ekspresijskog vektora, novi proizvodni postupci dobivanja stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20160208284A1 (hr) |
| EP (2) | EP2794651B1 (hr) |
| JP (4) | JP6096802B2 (hr) |
| KR (4) | KR102048556B1 (hr) |
| CN (4) | CN113881702A (hr) |
| CA (2) | CA2854249C (hr) |
| ES (1) | ES2930215T3 (hr) |
| HK (1) | HK1200848A1 (hr) |
| HR (1) | HRP20221383T1 (hr) |
| MX (2) | MX355624B (hr) |
| PL (1) | PL2794651T3 (hr) |
| RU (2) | RU2639519C2 (hr) |
| SG (3) | SG11201403443WA (hr) |
| WO (1) | WO2013092743A2 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11046975B2 (en) | 2013-10-07 | 2021-06-29 | Prestige Biopharma Pte. Ltd. | Bicistronic expression vector for antibody expression and method for producing antibody using same |
| CN105255867A (zh) * | 2015-10-19 | 2016-01-20 | 北京益生合生物科技有限公司 | 一种防止启动子在传代培养中逐渐灭活的基因序列及其应用 |
| US11028410B2 (en) | 2016-01-27 | 2021-06-08 | Just-Evotec Biologics, Inc. | Hybrid promoter and uses thereof |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| EP3528852A4 (en) | 2016-10-20 | 2020-06-03 | Sangamo Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY'S DISEASE |
| WO2018211529A1 (en) * | 2017-05-19 | 2018-11-22 | Council Of Scientific & Industrial Research | A method for producing refolded recombinant humanized ranibizumab |
| JP7081139B2 (ja) * | 2017-12-20 | 2022-06-07 | 東ソー株式会社 | 新規プロモーターおよびそれを含む発現ベクター |
| CA3206669A1 (en) | 2021-01-29 | 2022-08-04 | Mark A. BROWER | Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof |
| KR102640929B1 (ko) | 2023-06-02 | 2024-02-27 | (주) 멥스젠 | 미세생체조직시스템 형성 장치 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| JP3051411B2 (ja) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規ｄｎａならびにそれを含有する発現プラスミド |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| RU2201449C2 (ru) * | 1994-10-14 | 2003-03-27 | Сембайозис Дженетикс Инк. | Слитый полипептид, способный к целенаправленному переносу к масляному телу, химерная днк-контрукция, экспрессирующая кассета |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| IL136544A0 (en) | 1997-12-05 | 2001-06-14 | Scripps Research Inst | Humanization of murine antibody |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| DK2270150T4 (da) | 1999-04-09 | 2019-08-26 | Kyowa Hakko Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| KR100408844B1 (ko) | 2000-07-29 | 2003-12-06 | 한국산업기술평가원 | 동물세포 발현벡터 |
| PL218428B1 (pl) | 2000-10-06 | 2014-12-31 | Kyowa Hakko Kogyo Kk | Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| KR20100018071A (ko) | 2001-08-03 | 2010-02-16 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
| US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| JP2005535282A (ja) * | 2001-11-16 | 2005-11-24 | アイデック ファーマシューティカルズ コーポレイション | 抗体のポリシストロニック発現 |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| CA2481657A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| NZ556507A (en) | 2002-06-03 | 2010-03-26 | Genentech Inc | Synthetic antibody phage libraries |
| ES2347241T3 (es) | 2002-12-16 | 2010-10-27 | Genentech, Inc. | Variantes de inmunoglobulina y sus utilizaciones. |
| CN100383244C (zh) * | 2003-01-07 | 2008-04-23 | 西福根有限公司 | 用于生产重组多克隆蛋白质的方法 |
| AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| EP1688439A4 (en) | 2003-10-08 | 2007-12-19 | Kyowa Hakko Kogyo Kk | HYBRID PROTEIN COMPOSITION |
| AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| SG172616A1 (en) | 2004-04-13 | 2011-07-28 | Hoffmann La Roche | Anti-p-selectin antibodies |
| CN101001953B (zh) * | 2004-06-17 | 2013-03-13 | 惠氏公司 | 具有三个完整转录单元的质粒和用于诱导hiv免疫反应的免疫原性组合物 |
| BRPI0617688A2 (pt) * | 2005-10-21 | 2011-06-07 | Hoffmann La Roche | método para expressão recombinante de um polipeptìdeo |
| EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
| JP2010512765A (ja) * | 2006-12-22 | 2010-04-30 | エフ．ホフマン−ラ ロシュ アーゲー | 選択方法 |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CA2681581A1 (en) * | 2007-03-30 | 2008-10-09 | Abbott Laboratories | Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| AU2008271658B8 (en) * | 2007-06-29 | 2013-07-04 | F. Hoffmann-La Roche Ag | Promoter |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| WO2010022961A1 (en) * | 2008-08-28 | 2010-03-04 | Novartis Ag | Cell surface display of polypeptide isoforms by stop codon readthrough |
| GB0903207D0 (en) * | 2009-02-25 | 2009-04-08 | Ucb Pharma Sa | Method for expressing multimeric proteins |
| CN102369215B (zh) | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | 包含全长抗体和单链Fab片段的多特异性抗体 |
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
-
2012
- 2012-12-19 SG SG11201403443WA patent/SG11201403443WA/en unknown
- 2012-12-19 HR HRP20221383TT patent/HRP20221383T1/hr unknown
- 2012-12-19 CN CN202111170578.8A patent/CN113881702A/zh active Pending
- 2012-12-19 CN CN201710324350.7A patent/CN107119073A/zh active Pending
- 2012-12-19 KR KR1020147016825A patent/KR102048556B1/ko active IP Right Grant
- 2012-12-19 KR KR1020197034166A patent/KR102166824B1/ko active IP Right Grant
- 2012-12-19 KR KR1020207007391A patent/KR102229491B1/ko active IP Right Grant
- 2012-12-19 WO PCT/EP2012/076203 patent/WO2013092743A2/en active Application Filing
- 2012-12-19 EP EP12810245.6A patent/EP2794651B1/en active Active
- 2012-12-19 US US14/367,680 patent/US20160208284A1/en not_active Abandoned
- 2012-12-19 MX MX2014007359A patent/MX355624B/es active IP Right Grant
- 2012-12-19 KR KR1020217007341A patent/KR102285184B1/ko active IP Right Grant
- 2012-12-19 CA CA2854249A patent/CA2854249C/en active Active
- 2012-12-19 RU RU2014129727A patent/RU2639519C2/ru active
- 2012-12-19 CN CN202111171021.6A patent/CN113896787A/zh active Pending
- 2012-12-19 RU RU2017140661A patent/RU2756910C2/ru active
- 2012-12-19 PL PL12810245.6T patent/PL2794651T3/pl unknown
- 2012-12-19 CN CN201280062793.9A patent/CN104011075B/zh active Active
- 2012-12-19 EP EP18157484.9A patent/EP3354660A1/en active Pending
- 2012-12-19 SG SG10201700169PA patent/SG10201700169PA/en unknown
- 2012-12-19 MX MX2017012736A patent/MX370481B/es unknown
- 2012-12-19 SG SG10201900915WA patent/SG10201900915WA/en unknown
- 2012-12-19 JP JP2014547983A patent/JP6096802B2/ja active Active
- 2012-12-19 ES ES12810245T patent/ES2930215T3/es active Active
- 2012-12-19 CA CA3149402A patent/CA3149402A1/en active Pending
-
2015
- 2015-02-04 HK HK15101213.2A patent/HK1200848A1/xx unknown
-
2017
- 2017-02-16 JP JP2017026502A patent/JP6417436B2/ja active Active
-
2018
- 2018-10-05 JP JP2018189605A patent/JP2019030311A/ja active Pending
-
2019
- 2019-12-09 JP JP2019221805A patent/JP7096806B2/ja active Active
-
2020
- 2020-07-06 US US16/921,194 patent/US20210024952A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221383T1 (hr) | Kombinacije elemenata ekspresijskog vektora, novi proizvodni postupci dobivanja stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida | |
| HRP20190652T1 (hr) | Fuzijski proteini od prirodnih ljudskih proteinskih fragmenata za proizvodnju pravilno multimeriziranih fc-sastava imunoglobulina | |
| ES2679369T3 (es) | Anticuerpos de cadena ligera modificados mediante ingeniería con histidina y roedores modificados genéticamente para la generación de los mismos | |
| ES2678945T3 (es) | Cultivos celulares optimizados metabólicamente | |
| JP2011504721A5 (hr) | ||
| HRP20200744T1 (hr) | Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida | |
| ES2962489T3 (es) | Anticuerpos de cadena ligera diseñados genéticamente con histidina y animales no humanos modificados genéticamente para generar los mismos | |
| JP6162246B2 (ja) | キメラサイトメガロウイルスプロモーター配列およびエンハンサー配列を含む発現ベクター | |
| AU2018201094B2 (en) | Production cell line enhancers | |
| JP2016517691A5 (hr) | ||
| JP2019514417A5 (hr) | ||
| ES2626232T3 (es) | Vector de expresión de mamíferos | |
| JP2012090633A5 (hr) | ||
| ES2564227T3 (es) | Elemento de ADN que tiene actividad de aumento de expresión de un gen exógeno | |
| BR112014013597A2 (pt) | cassete de expressão, vetor de expressão, célula hospedeira, método in vitro para expressão de um polipeptídeo e uso de um cassete de expressão ou vetor de expressão | |
| AU2017206785C1 (en) | Rodents having an engineered heavy chain diversity region | |
| MX2012005117A (es) | Construcciones de sorf y expresion de gen multiple. | |
| JP2016506239A5 (hr) | ||
| RU2013123638A (ru) | Рекомбинантная плазмидная днк, кодирующая химерное антитело против фактора некроза опухоли-альфа человека, линия эукариотических клеток - продуцент химерного антитела и способ получения химерного антитела | |
| BR112020000406A2 (pt) | Plataforma genética para superexpressão heteróloga associada à seleção de células altamente produtoras de proteínas | |
| Mizutani et al. | Modified S/MAR episomal vectors for stably expressing fluorescent protein-tagged transgenes with small cell-to-cell fluctuations | |
| US20140011237A1 (en) | Chinese Hamster Ovary Cell Line | |
| RU2016152555A (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA2m1F16-ht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IGA2m1 | |
| RU2016152550A (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA1FI6-Intht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IgA1 | |
| KR101389088B1 (ko) | 염기서열 최적화된 나트륨-요오드 수송체 유전자 및 그 용도 |